P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
Abroad (travel likely)Active Not RecruitingPHASE3
Conditions
Primary Myelofibrosis · Myeloproliferative Neoplasm
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Levine Cancer Institute, Charlotte, North Carolina, United States
University of Yamanashi Hospital, Chūō, Yamanashi, Japan
Study leads
Toshiaki Sato, MD/PhD
Study Director
PharmaEssentia JP
View source on ClinicalTrials.gov(opens in a new tab)
No study contact email or phone is listed for this trial.